CIK 0001690585
- Non-accelerated filer
- Smaller reporting company
Dianthus Therapeutics, Inc. /DE/
Sign in to watch- Ticker
- DNTH
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 929-999-4055
- Business address
- 7 TIMES SQUARE, 43RD FLOOR, NEW YORK, NY, 10036
- Former names
- Magenta Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $15,717,056
- in 3 filings, $15.7M under 10b5-1 plans
Net −$15,717,056. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-07-09 | Savitz Ryan EVP, CFO & CBO | Sale 10b5-1 | −15,329 | $101.24 | $1.6M | 5,566 |
| 2026-07-09 | Savitz Ryan EVP, CFO & CBO | Sale 10b5-1 | −5,566 | $101.97 | $568K | 0 |
| 2026-06-17 | Veness Adam M SVP, General Counsel and Sec. | Sale 10b5-1 | −16,771 | $80.34 | $1.3M | 13,229 |
| 2026-06-17 | Veness Adam M SVP, General Counsel and Sec. | Sale 10b5-1 | −13,229 | $81.38 | $1.1M | 0 |
| 2026-06-01 | Randhawa Simrat EVP, Head of R&D | Sale 10b5-1 | −5,428 | $89.72 | $487K | 25,102 |
| 2026-06-01 | Randhawa Simrat EVP, Head of R&D | Sale 10b5-1 | −16,943 | $90.72 | $1.5M | 8,159 |
| 2026-06-01 | Randhawa Simrat EVP, Head of R&D | Sale 10b5-1 | −4,159 | $91.37 | $380K | 4,000 |
| 2026-05-08 | Soteropoulos Paula Director | Sale 10b5-1 | −599 | $85.47 | $51K | 0 |
| 2026-04-09 | Savitz Ryan EVP, CFO & CBO | Sale 10b5-1 | −8,224 | $89.84 | $739K | 0 |
| 2026-03-31 | Savitz Ryan EVP, CFO & CBO | Sale 10b5-1 | −1,390 | $78.33 | $109K | 112,977 |
| 2026-03-31 | Savitz Ryan EVP, CFO & CBO | Sale 10b5-1 | −21,825 | $78.86 | $1.7M | 91,152 |
| 2026-03-31 | Savitz Ryan EVP, CFO & CBO | Sale 10b5-1 | −1,485 | $80.25 | $119K | 89,667 |
| 2026-03-31 | Savitz Ryan EVP, CFO & CBO | Sale 10b5-1 | −800 | $81.36 | $65K | 88,867 |
| 2026-03-31 | Savitz Ryan EVP, CFO & CBO | Sale 10b5-1 | −2,366 | $82.84 | $196K | 86,501 |
| 2026-03-31 | Savitz Ryan EVP, CFO & CBO | Sale 10b5-1 | −59,800 | $83.90 | $5.0M | 26,701 |
| 2026-03-31 | Savitz Ryan EVP, CFO & CBO | Sale 10b5-1 | −19,469 | $84.57 | $1.6M | 7,232 |
| 2026-03-31 | Savitz Ryan EVP, CFO & CBO | Sale 10b5-1 | −7,232 | $85.54 | $619K | 0 |
| 2026-03-31 | Soteropoulos Paula Director | Sale 10b5-1 | −599 | $80.11 | $48K | 0 |
| 2026-03-24 | Soteropoulos Paula Director | Sale 10b5-1 | −27,594 | $78.05 | $2.2M | 0 |
| 2026-03-12 | Randhawa Simrat EVP, Head of R&D | Sale 10b5-1 | −33,830 | $81.48 | $2.8M | 0 |
Page 3 of 6 · 119 trades